The Spectra Optia system is the first and only therapeutic apheresis system on the European market today with an indication to treat myasthenia gravis (MG) and Guillain-Barré syndrome (GBS) for specific patient populations.* (Chevret et al., 2017) (Cortese et al., 2011) (Sanders et al., 2016) (Elovaara et al., 2008) (Schwartz et al., 2016) Using plasma exchange delivers a rapid clinical response resulting in a fast road to recovery.
*As of December 2016.
Evidence-Based Guidance for Plasma Exchange in MG and GBS
1Elovaara I, et al. Eur J Neurol. 2008; 15:893-908. 2Raphaël JC, et al. Cochrane Database Syst Rev. 2012(7). 3Schwartz J, et al. J Clin Apher. 2016; 31(3):149-162. 4Sanders DB, et al. Neurology. 2016; 87(4):419-425.
Class I (Level A for severe GBS)
Category I (Grade 1A) and Category III (Grade 2C)
1Cortese I, et al. Neurology. 2011; 76:294-300. 2Schwartz J, et al. J Clin Apher. 2016; 31(3):149-162. 3Elovaara I, et al. Eur J Neurol. 2008; 15:893-908.
Possible patient reactions
Reactions to transfused blood products can include1
Restricted to prescription use only
1AABB (ed.), et al., Circular of Information for the Use of Human Blood and Blood Components. 2006, tenth edition, Council of Europe Publishing, Seattle, WA.
2American Society for Apheresis. Guidelines for therapeutic apheresis clinical privileges. J Clin Apher. 2007;22(3):181-182.
International Content. Approved labeling, indications and instructions may vary by country. Reference the Instructions for Use labeling for a complete listing of indications, warnings and precautions.
Products available in select markets.